Literature DB >> 10922227

Antisense inhibition of cyclin D1 in human head and neck squamous cell carcinoma.

T Nakashima1, G L Clayman.   

Abstract

OBJECTIVE: To study the role of cyclin D1 in regulating the biological behavior of head and neck cancer.
DESIGN: Squamous cell carcinoma of the head and neck (SCCHN) cells were stably transfected with an antisense cyclin D1 using lipofectin-mediated transfection. In vitro growth assays, cell cycle analyses, cytotoxicity assays, and in vivo tumorigenicity assays were performed. MATERIALS: Human SCCHN cell lines TU138, TU167, TU177, TU182, MDA183, and MDA1386 and athymic nude mice were used for this study.
RESULTS: The antisense cyclin D1 transfected cells revealed decreased growth rates in vitro and decreased tumorigenicity in athymic nude mice. Furthermore, antisense cyclin D1 transfection enhanced the chemosensitivity against cisplatin.
CONCLUSIONS: These studies provided evidence that overexpression of cyclin D1 may play an important role in growth rates and biological behavior of human head and neck cancer. Additionally, expression of cyclin D1 may make human head and neck cancer cells resistant to platinum-based chemotherapeutic approaches. The ability to suppress the malignant phenotype by down-regulating cyclin D1 expression may provide a new gene therapy approach for patients with head and neck cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10922227     DOI: 10.1001/archotol.126.8.957

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  8 in total

1.  Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context.

Authors:  Wen-Liang Kuo; Jing Liu; Helena Mauceri; Everett E Vokes; Ralph Weichselbaum; Marsha Rich Rosner; Ezra Eddy Wyssam Cohen
Journal:  Mol Cancer Ther       Date:  2010-09-28       Impact factor: 6.261

2.  Head and Neck Squamous Cell Cancer: Biology (II) and Translational Methods.

Authors:  Anupam Mishra; Amita Pandey; Xiaolin Nong
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2007-10-05

3.  The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers.

Authors:  Elodie E Noel; Marc Yeste-Velasco; Xueying Mao; Jackie Perry; Sakunthala C Kudahetti; Ningfeng F Li; Swee Sharp; Tracy Chaplin; Liyan Xue; Alan McIntyre; Ling Shan; Thomas Powles; R Tim D Oliver; Bryan D Young; Janet Shipley; Daniel M Berney; Simon P Joel; Yong-Jie Lu
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

4.  Cyclin D1 polymorphism and expression in patients with squamous cell carcinoma of the head and neck.

Authors:  S L Holley; G Parkes; C Matthias; U Bockmühl; V Jahnke; K Leder; R C Strange; A A Fryer; P R Hoban
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

5.  Cyclin D1 overexpression enhances chemosensitivity to TPF chemotherapeutic agents via the caspase-3 pathway in oral cancer.

Authors:  Yong-Jie Hu; Wen-Wen Sun; Tong-Chao Zhao; Ying Liu; Dong-Wang Zhu; Li-Zhen Wang; Jiang Li; Chen-Ping Zhang; Zhi-Yuan Zhang; Lai-Ping Zhong
Journal:  Oncol Lett       Date:  2020-08-24       Impact factor: 2.967

6.  Cyclin D1 expression does not effect cell proliferation in adenoid cystic carcinoma of the salivary gland.

Authors:  Ryuji Yasumatsu; Yuichiro Kuratomi; Torahiko Nakashima; Muneyuki Masuda; Tomoya Yamamoto
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-01-09       Impact factor: 2.503

7.  The effect of cyclin D1 overexpression in human head and neck cancer cells.

Authors:  Torahiko Nakashima; Yuichiro Kuratomi; Ryuji Yasumatsu; Muneyuki Masuda; Koji Koike; Toshiro Umezaki; Gary L Clayman; Takashi Nakagawa; Shizuo Komune
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-09-11       Impact factor: 2.503

8.  Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer.

Authors:  Yuh Baba; Masato Fujii; Yutaka Tokumaru; Yasumasa Kato
Journal:  J Oncol       Date:  2012-03-26       Impact factor: 4.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.